CQDM funds a project to improve the screening of lung cancer with BioMark Diagnostic Solutions, in partnership with AstraZeneca, Pfizer Canada and the IUCPQ Foundation

News & Events

MONTREAL, November 30, 2021 – During this Lung Cancer Awareness Month, CQDM is proud to announce that it will co-fund a project driven by Dr Philippe Joubert and Pr. Yohan Bossé at the Quebec Heart and Lung Institute (Institut Universitaire de Cardiologie et Pneumologie du Québec-Université Laval – IUCPQ-UL) targeting a program of early-stage detection of lung cancer. Funding for … Read More

ADRIQ* 2021 AWARD – CQDM congratulates Feldan Therapeutics for receiving the 2021 ADRIQ RSRI (regroupements sectoriels de recherche industrielle) award.

News & Events

MONTREAL, November 25, 2021 – The 2021 ADRIQ biopharmaceutical sector RSRI award was presented to Feldan Therapeutics, a Quebec City-based company that CQDM has been funding since 2018 as part of a collaborative research project. This project brought together a group of five major pharmaceutical companies, the Quebec biotech Feldan and academic institutions to validate and advance the Feldan Shuttle, … Read More

We are hiring! Financial controller – Apply now!

Job offers

ABOUT CQDM  Since its creation, CQDM has raised nearly $100 million to fund the development of approximately 80 outstanding technologies addressing major health challenges, including cancer, neurodegenerative and metabolic diseases. CQDM is a biopharmaceutical research consortium whose mission is to fund the development of innovative tools and technologies that accelerate the development of safe and effective drugs. We bring together world-leading pharmaceutical … Read More

2021 Sweet Pharma Day Winner is HDAX Therapeutics

News & Events

Montréal, Canada – (BUSINESSWIRE) October 8, 2021 – AmorChem, BioQuébec and CQDM, co-organizers of Sweet Pharma Day, are pleased to announce that HDAX Therapeutics is the winner of the 2021 edition. Sixteen Canadian startup companies (“Sweet 16”) selected by representatives from global pharma companies, made an elevator pitch in front of 150+ participants, who voted for HDAX Therapeutics as the … Read More

A new partnership between CQDM, the Canadian Cancer Society, the Cole Foundation and Oncopole to support pediatric cancer research

News & Events

Montreal – October 7, 2021 – CQDM, the Canadian Cancer Society (CCS), the Cole Foundation (CF) and Oncopole – Pôle cancer du FRQS launch a first call for proposals to support collaborative R&D projects focusing on pediatric and young adult cancers, in particular leukemia and lymphoma. This new research funding, worth up to $5M, builds on CCS, CF, Oncopole and … Read More

CQDM invests in Montreal-based regenerative medicine company, Morphocell Technologies

News & Events

CQDM invests in Montreal-based regenerative medicine company, Morphocell Technologies, to support the development of innovative therapies for acute liver failure Montréal – Québec – July 7 – CQDM is proud to announce an investment of $260,100 in Morphocell Technologies, a Montréal- based early-stage regenerative medicine company focused on the development of stem cell-derived engineered liver tissue to treat liver disease. … Read More

CQDM invests $500,000 in Giiant Pharma, a Quebec-based pharmaceutical company with strong potential in gastroenterology

News & Events

Montreal – June 30th 2021 – CQDM is proud to invest in Giiant Pharma’s seed financing round, joining co-leads Amplitude Ventures and Genesys Capital, along with Fonds de solidarité FTQ, AmorChem II Fund, Theodorus Investment Funds, AQC Capital, Anges Québec, and other angel investor. This financing will enable Giiant Pharma to become a leader in targeted drug delivery technologies to … Read More

CQDM to fund an international collaboration between Raya Therapeutic, Eikonizo Therapeutics and McGill University

News & Events

CQDM to fund an international collaboration between Raya Therapeutic, Eikonizo Therapeutics and McGill University to develop new treatments for Amyotrophic Lateral Sclerosis (ALS) MONTREAL, June 21, 2021 – On this Global Amyotrophic Lateral Sclerosis (ALS) Awareness Day, CQDM is proud to announce a new $1.7M international collaboration between McGill University, Raya Therapeutic (Montreal – Quebec) and Eikonizo Therapeutics (Cambridge – … Read More

CQDM sets up a collaboration between Simon Fraser University, Amgen, Merck, Servier and GlycoNet

Funded Projects, News & Events

CQDM sets up a collaboration between Simon Fraser University, Amgen, Merck, Servier and GlycoNet to develop new chemistry to facilitate drug development and manufacturing MONTREAL, June 2nd, 2021 – CQDM is proud to announce a partnership with 3 major pharmaceutical companies, Amgen Canada, Merck Canada, Servier Canada and the Canadian Glycomics Network (GlycoNet) as part of a $1,251,900 funding project. … Read More

Accélérer le passage de l’idée au marché – Dépôt du mémoire des RSRI

News & Events

Accélérer le passage de l’idée au marché – Dépôt du mémoire des RSRI dans le cadre des consultations publiques sur la Stratégie québécoise de la recherche et de l’innovation 2022. (Québec, le 31 mai 2021) – Les regroupements sectoriels de recherche industrielle (RSRI) ont déposé leurs propositions pour stimuler l’innovation dans le cadre des consultations publiques sur la Stratégie québécoise … Read More